AbbVie (ABBV) Says Risankizumab Met All Co-Primary and Ranked Secondary Endpoints in Three Pivotal Phase 3 Psoriasis Studies
Tweet Send to a Friend
AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced positive top-line results from three pivotal Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
